{"id":58551,"date":"2023-12-09T19:02:26","date_gmt":"2023-12-09T18:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/"},"modified":"2023-12-09T19:02:26","modified_gmt":"2023-12-09T18:02:26","slug":"scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/","title":{"rendered":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma"},"content":{"rendered":"
\n

\nSC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma<\/i><\/p>\n

\nData presented today, December 9, at the 65th<\/sup> ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York<\/i><\/p>\n

AMSTERDAM, the Netherlands–(BUSINESS WIRE)–Scenic Biotech<\/a>, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, at the 65th<\/sup> American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. The new preclinical data covers results for SC-2882, Scenic\u2019s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL). DLBCL accounts for 25-30% of all non-Hodgkin lymphoma cases, making it the most common cancer of the lymphatic system characterized by rapidly growing tumor mass or enlarging lymph nodes in a nodal or extranodal site.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cTreatment with SC-2882 in a DLBCL mice model achieved a significant decrease in tumor growth and an increase of CD3+ T cell infiltration within the tumor microenvironment, along with a reduction in immunosuppressive immune cells. This suggests that QPCTL inhibition in DLBCL has anti-lymphoma effects and holds potential as a new therapeutic avenue for this type of cancer,\u201d commented Leandro Cerchietti, MD, Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, and presenter at the 65th<\/sup> ASH Annual Meeting & Exposition.<\/b><\/p>\n

\n\u201cThe positive preclinical data presented today constitute a major step forward in the advance of SC-2882 as a potential treatment for DLBCL, an indication with high unmet medical need especially in post-CART relapsed or refractory DLBCL patients, as well as in earlier lines of treatment with non-chemotherapy or immuno-oncology-based approaches. QPCTL was identified as a new immuno-oncology target through our proprietary Cell-Seq platform, and we view these results as a validation for our approach and our earlier-staged Cell-Seq-generated programs in rare diseases,\u201d commented Jens W\u00fcrthner, MD, PhD, CMO of<\/b> Scenic Biotech<\/b>. \u201cAs we finalize IND-enabling studies for SC-2882, we look forward to submitting our initial clinical trial filing to the regulatory authorities in 2024 and moving into clinical evaluation.\u201d<\/p>\n

\nQPCTL is an intracellular enzyme that modulates the activity of CD47 and several chemokines in cancer leading to immune escape of cancer cells. SC-2882 targets QPCTL and thereby inhibits the CD47-SIRP\u03b1 \u201cdon\u2019t eat me\u201d checkpoint and lowers immune suppression in the tumor microenvironment. Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival. In a murine model of DLBCL, SC-2882 treatment led to a significant decrease in tumor growth with no evidence of systemic toxicity. Moreover, evaluation of the tumor microenvironment (TME) showed an increased CD3+ T cell infiltration and a reduction in tumor-associated macrophages and regulatory T cells in SC-2882-treated mice, compared to control. These results imply SC-2882 exhibits an anti-tumor effect that involves modulation of immunosuppression in the TME.<\/p>\n

\nThe data was described today in an oral presentation by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York, at 9:30 AM PST\/ 18:30 CET during session 605 entitled \u201cMolecular Pharmacology and Drug Resistance – Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma\u201d.<\/p>\n

\nAbout Scenic Biotech<\/b><\/p>\n

\nScenic Biotech is at the forefront of identifying genetic modifiers, naturally occurring genes that compensate for mutations responsible for severe diseases. Leveraging our proprietary Cell-Seq platform, we develop small molecule inhibitors that mimic the modifier effect and neutralize the genetic disease phenotype. As we advance a robust pipeline of first-in-class modifier therapies, we aim to re-balance health in patients with life-threatening inherited disorders.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:<\/b><\/p>\n

\nS<\/b>cenic Biotech<\/b>
Oscar Izeboud, PhD, CEO
\n
Phone: +31 6 51 06 27 97
\n
Email: oscar.izeboud@scenicbiotech.com<\/a><\/p>\n

\nTrophic Communications<\/b>
Desmond James & Priscillia Perrin, PhD
\n
Phone: +49 151 6785 9086
\n
Email: scenic@trophic.eu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York AMSTERDAM, the Netherlands–(BUSINESS WIRE)–Scenic … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58551","6":"format-standard","7":"category-industry"},"yoast_head":"\nScenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York AMSTERDAM, the Netherlands–(BUSINESS WIRE)–Scenic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-09T18:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma\",\"datePublished\":\"2023-12-09T18:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/\"},\"wordCount\":687,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231209805990\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/\",\"name\":\"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231209805990\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"datePublished\":\"2023-12-09T18:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231209805990\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231209805990\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend","og_description":"SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York AMSTERDAM, the Netherlands–(BUSINESS WIRE)–Scenic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/","og_site_name":"Pharma Trend","article_published_time":"2023-12-09T18:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma","datePublished":"2023-12-09T18:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/"},"wordCount":687,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/","url":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/","name":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg","datePublished":"2023-12-09T18:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231209805990\/en\/822873\/21\/LOGO_SB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-announces-positive-preclinical-data-for-its-qpctl-inhibitor-sc-2882-as-potential-new-therapeutic-approach-for-diffuse-large-b-cell-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58551"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58551\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}